Current Peptide Compliance

Adverse event reporting is one of the most critical — and most frequently mishandled — compliance obligations for peptide manufacturers and distributors. The FDA requires timely, accurate reporting of adverse experiences associated with marketed drug products, and failure to report can result in warning letters, consent decrees, and criminal liability.

When Reporting Is Required

Any adverse experience that comes to your attention — whether reported by a healthcare provider, patient, or identified through your own monitoring — must be evaluated and potentially reported. Serious adverse events, including death, hospitalization, disability, or life-threatening experiences, must be reported to the FDA within 15 calendar days via MedWatch Form 3500A. Non-serious events must be reported in periodic safety reports.

Building Your Reporting System

An effective adverse event reporting system requires several components: a documented intake process for receiving reports from any source, trained personnel who can evaluate causality and seriousness, standardized forms and workflows for consistent documentation, escalation procedures with defined timelines, MedWatch submission capabilities, and a tracking database that supports trend analysis and signal detection.

Common Mistakes to Avoid

The most frequent compliance failures in adverse event reporting include late submissions that exceed the 15-day serious event deadline, inadequate causality assessments, failure to follow up on incomplete initial reports, poor documentation that cannot withstand FDA audit scrutiny, and lack of a formal process for evaluating whether a cluster of events represents a safety signal requiring broader action.

Need to build or improve your adverse event reporting system? Current Peptide Compliance designs pharmacovigilance programs purpose-built for peptide operations. Contact us to get started.